Why the study?
Does the combination of thromboxane and serotonin receptor antagonists enhance thrombolysis and prevent reocclusion in canine models of coronary thrombosis?
Does the combination of thromboxane and serotonin receptor antagonists enhance thrombolysis and prevent reocclusion in canine models of coronary thrombosis?
In canine models, adding thromboxane and serotonin receptor antagonists to tPA and heparin enhances thrombolysis and prevents reocclusion.
Does not support clinical adoption; leaves open whether adjunctive receptor blockade augments thrombolysis in patients.
Changes in a coronary artery thrombus resulting from platelet activation may affect the speed of thrombolysis and the frequency of reocdusion after thrombolytic therapy. In studies performed in canine models, we have found that selected thromboxane and serotonin receptor antagonists given in combination markedly enhance the thrombolytic effect of tissue plasminogen activator, probably by preventing further platelet activation and their incorporation into a thrombus during thrombolytic therapy. The combination of a thromboxane and serotonin receptor antagonist given with heparin and tissue plasminogen activator is effective in delaying or preventing reocdusion after discontinuation of tissue plasminogen activation in experimental canine models in whom coronary artery thrombosis has been induced by an indwelling copper coil.
No takes yet. Share an insight, caveat, or question.
Willerson et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: